NCT06468826View on ClinicalTrials.gov

A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD)

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

July 11, 2024

Primary Completion Date

October 5, 2024

Study Completion Date

October 5, 2024

Conditions
End-Stage Renal Disease (ESRD)
Interventions
DRUG

Avacopan

Oral capsules

Trial Locations (2)

33016

Floridian Clinical Research, LLC, Miami Lakes

32809-3017

Orlando Clinical Research Center, Orlando

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT06468826 - A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD) | Biotech Hunter | Biotech Hunter